¹Ú°æÈ­ ¸íÀÇ

À¯¹æ¾Ï Á¤¹ÐÀÇÇÐ ±â¹Ý Ç׾ϡ¤Ç¥Àû¡¤¸é¿ª Ä¡·á¸¦ ¼³°èÇÏ´Â ¾ÏÄ¡·á ¸íÀÇ

¹Ú°æÈ­ ¸íÀÇ

  • ¼Ò ¼Ó
    °í·Á´ëÇб³ ¾È¾Ïº´¿ø
  • Áø·á°ú
    Á¾¾ç³»°ú
  • Àü¹®ºÐ¾ß
    À¯¹æ¾Ï,ºÎÀξÏ,ºñ´¢±â¾Ï,À¯Àü¼º¾Ï À¯Àü»ó´ã

°í·Á´ë ¾È¾Ïº´¿ø Á¾¾çÇ÷¾×³»°ú ±³¼ö. À¯¹æ¾Ï¡¤ºÎÀÎ¾Ï ¹× À¯Àü¼º¾Ï Àü½ÅÄ¡·á¿Í Á¤¹ÐÀÇÇÐÀÌ Àü¹®ÀÌ´Ù. ¼ö¼ú ÀüÈÄ Ç׾ϡ¤È£¸£¸ó¡¤Ç¥ÀûÄ¡·á¡¤ ¸é¿ªÇ×¾ÏÁ¦ µî ÃֽŠġ·áÁ¦¸¦ ȯÀÚº° À¯ÀüÀÚ¡¤º´±â¿¡ ¸ÂÃç Á¶ÇÕÇÑ´Ù. ±¹³»¿Ü ÀÓ»ó½ÃÇè°ú Á¾¾ç¹é½Å¡¤¸é¿ªÇ×¾Ï ¿¬±¸¿¡ Âü¿©Çϸç, ¾ÏÄ¡·á Ŭ¸®´Ð¡¤Á¤¹ÐÀÇÇÐŬ¸®´Ð Áø·á¸¦ ÅëÇØ Àç¹ß À§ÇèÀ» ³·Ãß°í Àå±â »ýÁ¸°ú »îÀÇ Áú Çâ»óÀ» µ¿½Ã¿¡ Ãß±¸ÇÑ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °í·Á´ë ÀÇ´ë Çлç
  • °í·Á´ë ÀÇ´ë ¹Ú»ç
  • University of Washington, Tumor vaccine group ¿¬¼ö

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °í·Á´ëÇб³ ¾È¾Ïº´¿ø Á¾¾çÇ÷¾×³»°ú ±³¼ö
  • University of Washington, Tumor vaccine group ¹æ¹®±³¼ö (2014 ~ 2015)
  • °í·Á´ëÇб³ ±¸·Îº´¿ø Á¾¾çÇ÷¾×³»°ú ÀüÀÓÀÇ (2004 ~ 2005)
  • °í·Á´ëÇб³ ¾È¾Ïº´¿ø ÀÎÅÏ, ³»°ú Àü°øÀÇ (1998 ~ 2003)

ÇÐȸȰµ¿

Academic activities
  • ¹Ì±¹ ¾Ï ¿¬±¸ÇÐȸ ȸ¿ø
  • À¯·´Á¾¾ç³»°úÇÐȸ ȸ¿ø
  • ´ëÇÑ Ç׾Ͽä¹ý ¿¬±¸È¸ ȸ¿ø, ÀÌ»ç
  • ´ëÇÑÁ¾¾ç³»°úÇÐȸ ȸ¿ø
  • ´ëÇÑ ¾ÏÇÐȸ ȸ¿ø, ÇмúÀÌ»ç
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 2°Ç
Á¦ ¸ñ Concurrent chemoradiation followed by adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma in Korea
¹ßÇ¥³âµµ 2009 ¹ßÇ¥Áö Cancer chemotherapy and pharmacology
Á¦ ¸ñ Insulin-like growth factor-binding protein 2 is a target for the immunomodulation of breast cancer
¹ßÇ¥³âµµ 2008 ¹ßÇ¥Áö Cancer Research

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

À¯¹æ¾Ï µî °íÇü¾Ï¿¡¼­ Á¤¹ÐÀÇÇÐ ±â¹Ý Ç׾ϡ¤Ç¥Àû¡¤¸é¿ªÄ¡·á°¡ ÇÙ½É °ü½É ºÐ¾ßÀÔ´Ï´Ù. ±¹³»¿Ü ÀÓ»ó½ÃÇè°ú Á¾¾ç¹é½Å ¿¬±¸¸¦ ÅëÇØ ȯÀÚº° ¸ÂÃã Ä¡·á Àü·«À» Á¦½ÃÇϰí, °íÀ§Ç衤Àç¹ß À§Çè ȯÀÚÀÇ Àå±â »ýÁ¸ Çâ»ó¿¡ ±â¿©ÇØ ¿Ô½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¼öÄ¡¿Í µ¥ÀÌÅÍ»Ó ¾Æ´Ï¶ó ȯÀÚÀÇ »îÀ» ÇÔ²² º¸´Â °ÍÀ» Áß¿äÇÏ°Ô ¿©±é´Ï´Ù. Ä¡·á ¸ñÇ¥¿Í ºÎÀÛ¿ë, ³²Àº »îÀÇ °èȹ¿¡ ´ëÇØ ÃæºÐÈ÷ °øÀ¯Çϸç Çö½ÇÀûÀÎ ÃÖ¼±ÀÇ Ä¡·á¸¦ ã°íÀÚ ÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Áø´Ü°ú Ä¡·á °úÁ¤ÀÌ ³¸¼³°í µÎ·Á¿ì½Ç ¼ö ÀÖÁö¸¸, ¾Ï Ä¡·á´Â °è¼Ó ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÚ½ÅÀÇ ¸ö°ú »îÀ» Áö۱â À§ÇØ ÀÌ¹Ì Å« ¿ë±â¸¦ ³»½Å ¸¸Å­, ³¡±îÁö Èñ¸ÁÀ» ³õÁö ¾Ê°í ¾ÕÀ¸·ÎÀÇ ½Ã°£À» ÇÔ²² ÁغñÇØ °¡±æ ÀÀ¿øÇÕ´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°í·Á´ëÇб³ ¾È¾Ïº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-0083
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°í·Á´ëÇб³ ¾È¾Ïº´¿øÀº 1056º´»ó ±Ô¸ð¸¦ °®Ãá »ó±ÞÁ¾ÇÕº´¿øÀ¸·Î¼­ ÁßÁõ ¹× ±Þ¼º±â ÁúȯÀ» Áß½ÉÀ¸·Î ´Ù¾çÇÑ Æ¯¼ºÈ­¼¾Å͸¦ ¿î¿µÇϰí ÀÖ´Ù. º´¿ø Àü¹Ý¿¡ ½º¸¶Æ® ÇコÄÉ¾î ½Ã½ºÅÛÀ» µµÀÔÇØ º¸´Ù Á¤È®ÇÏ°í ¾ÈÀüÇÑ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, ±¹°¡ÁöÁ¤ ¿¬±¸Á߽ɺ´¿øÀ¸·Î ¿¬¼Ó ÁöÁ¤µÇ´Â µî ¿¬±¸ ¿ª·®ÀÇ ¿ì¼ö¼ºÀ» ÀÎÁ¤¹Þ°í ÀÖ´Ù.

°í·Á´ëÇб³ ¾È¾Ïº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼ººÏ±¸ °í·Á´ë·Î 73 °í·Á´ëÇб³ ¾È¾Ïº´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä